{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T16:02:37Z","timestamp":1784649757200,"version":"3.55.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"32","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,8,25]]},"DOI":"10.1038\/s41388-025-03466-1","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T22:25:00Z","timestamp":1748643900000},"page":"2864-2875","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["LOXL2 reduces susceptibility to PARP inhibitors by promoting super-enhancer-regulated DNA damage repair in high-grade serous ovarian cancer"],"prefix":"10.1038","volume":"44","author":[{"given":"Chunyan","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chujun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangjia","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5748-4697","authenticated-orcid":false,"given":"Jiahong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kairong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zikun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangnian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3412-8208","authenticated-orcid":false,"given":"Yong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2360-2035","authenticated-orcid":false,"given":"Ding","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9971-2264","authenticated-orcid":false,"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"key":"3466_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3466_CR2","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69:280\u2013304.","journal-title":"CA Cancer J Clin"},{"key":"3466_CR3","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393:1240\u201353.","journal-title":"Lancet"},{"key":"3466_CR4","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495\u2013505.","journal-title":"N Engl J Med"},{"key":"3466_CR5","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, et al. Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416\u201328.","journal-title":"N Engl J Med"},{"key":"3466_CR6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381:2391\u2013402.","journal-title":"N Engl J Med"},{"key":"3466_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research N.","year":"2011","unstructured":"Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","journal-title":"Nature"},{"key":"3466_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer. 2020;19:107.","journal-title":"Mol Cancer"},{"key":"3466_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","volume":"150","author":"MA Dawson","year":"2012","unstructured":"Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:12\u201327.","journal-title":"Cell"},{"key":"3466_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.semcancer.2020.12.022","volume":"83","author":"L Guo","year":"2022","unstructured":"Guo L, Lee YT, Zhou Y, Huang Y. Targeting epigenetic regulatory machinery to overcome cancer therapy resistance. Semin Cancer Biol. 2022;83:487\u2013502.","journal-title":"Semin Cancer Biol"},{"key":"3466_CR11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.ccell.2016.09.002","volume":"30","author":"NE Muvarak","year":"2016","unstructured":"Muvarak NE, Chowdhury K, Xia L, Robert C, Choi EY, Cai Y, et al. Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents - a potential therapy for cancer. Cancer Cell. 2016;30:637\u201350.","journal-title":"Cancer Cell"},{"key":"3466_CR12","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-18-0204","volume":"24","author":"N Pulliam","year":"2018","unstructured":"Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer H, et al. An effective epigenetic-PARP inhibitor combination therapy for breast and ovarian cancers independent of BRCA mutations. Clin Cancer Res. 2018;24:3163\u201375.","journal-title":"Clin Cancer Res"},{"key":"3466_CR13","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.18632\/oncotarget.2154","volume":"5","author":"K Ha","year":"2014","unstructured":"Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, et al. Histone deacetylase inhibitor treatment induces \u2018BRCAness\u2019 and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget. 2014;5:5637\u201350.","journal-title":"Oncotarget"},{"key":"3466_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrd4583","volume":"14","author":"M Guha","year":"2015","unstructured":"Guha M. HDAC inhibitors still need a home run, despite recent approval. Nat Rev Drug Discov. 2015;14:225\u20136.","journal-title":"Nat Rev Drug Discov"},{"key":"3466_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0945-053X(98)90012-9","volume":"16","author":"LI Smith-Mungo","year":"1998","unstructured":"Smith-Mungo LI, Kagan HM. Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol. 1998;16:387\u201398.","journal-title":"Matrix Biol"},{"key":"3466_CR16","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1158\/1541-7786.MCR-13-0033-T","volume":"11","author":"HE Barker","year":"2013","unstructured":"Barker HE, Bird D, Lang G, Erler JT. Tumor-secreted LOXL2 activates fibroblasts through FAK signaling. Mol Cancer Res. 2013;11:1425\u201336.","journal-title":"Mol Cancer Res"},{"key":"3466_CR17","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1158\/0008-5472.CAN-10-2868","volume":"71","author":"HE Barker","year":"2011","unstructured":"Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, et al. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res. 2011;71:1561\u201372.","journal-title":"Cancer Res"},{"key":"3466_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-019-0144-0","volume":"8","author":"F Mahjour","year":"2019","unstructured":"Mahjour F, Dambal V, Shrestha N, Singh V, Noonan V, Kantarci A, et al. Mechanism for oral tumor cell lysyl oxidase like-2 in cancer development: synergy with PDGF-AB. Oncogenesis. 2019;8:34.","journal-title":"Oncogenesis"},{"key":"3466_CR19","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nrc1457","volume":"4","author":"N Turner","year":"2004","unstructured":"Turner N, Tutt A, Ashworth A. Hallmarks of \u2018BRCAness\u2019 in sporadic cancers. Nat Rev Cancer. 2004;4:814\u20139.","journal-title":"Nat Rev Cancer"},{"key":"3466_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03590-5","volume":"9","author":"D Liu","year":"2018","unstructured":"Liu D, Zhang XX, Li MC, Cao CH, Wan DY, Xi BX, et al. C\/EBPbeta enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation. Nat Commun. 2018;9:1739.","journal-title":"Nat Commun"},{"key":"3466_CR21","doi-asserted-by":"publisher","first-page":"bat013","DOI":"10.1093\/database\/bat013","volume":"2013","author":"BF Ganzfried","year":"2013","unstructured":"Ganzfried BF, Riester M, Haibe-Kains B, Risch T, Tyekucheva S, Jazic I, et al. curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome. Database. 2013;2013:bat013.","journal-title":"Database"},{"key":"3466_CR22","doi-asserted-by":"crossref","unstructured":"Papakonstantinou E, Pappa I, Androutsopoulos G, Adonakis G, Maroulis I, Tzelepi V. Comprehensive analysis of DNA methyltransferases expression in primary and relapsed ovarian carcinoma. Cancers. 2023;15:4950.","DOI":"10.3390\/cancers15204950"},{"key":"3466_CR23","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1158\/1541-7786.MCR-10-0398","volume":"8","author":"H Li","year":"2010","unstructured":"Li H, Cai Q, Godwin AK, Zhang R. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res. 2010;8:1610\u20138.","journal-title":"Mol Cancer Res"},{"key":"3466_CR24","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.7150\/jca.44475","volume":"11","author":"Y Xu","year":"2020","unstructured":"Xu Y, Pan S, Song Y, Pan C, Chen C, Zhu X. The prognostic value of the chromobox family in human ovarian cancer. J Cancer. 2020;11:5198\u2013209.","journal-title":"J Cancer"},{"key":"3466_CR25","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1158\/0008-5472.925.65.3","volume":"65","author":"L Zhang","year":"2005","unstructured":"Zhang L, Yang N, Huang J, Buckanovich RJ, Liang S, Barchetti A, et al. Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth. Cancer Res. 2005;65:925\u201332.","journal-title":"Cancer Res"},{"key":"3466_CR26","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s13577-020-00469-w","volume":"34","author":"T Guo","year":"2021","unstructured":"Guo T, Yuan D, Zhang W, Zhu D, Xiao A, Mao G, et al. Upregulation of long noncoding RNA XIST has anticancer effects on ovarian cancer through sponging miR-106a. Hum Cell. 2021;34:579\u201387.","journal-title":"Hum Cell"},{"key":"3466_CR27","doi-asserted-by":"publisher","first-page":"10602","DOI":"10.1158\/0008-5472.CAN-05-2240","volume":"65","author":"T Bonome","year":"2005","unstructured":"Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005;65:10602\u201312.","journal-title":"Cancer Res"},{"key":"3466_CR28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.molonc.2012.12.007","volume":"7","author":"B Stordal","year":"2013","unstructured":"Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, et al. BRCA1\/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol Oncol. 2013;7:567\u201379.","journal-title":"Mol Oncol"},{"key":"3466_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3126","volume":"4","author":"S Domcke","year":"2013","unstructured":"Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013;4:2126.","journal-title":"Nat Commun"},{"key":"3466_CR30","doi-asserted-by":"publisher","first-page":"e103988","DOI":"10.1371\/journal.pone.0103988","volume":"9","author":"CM Beaufort","year":"2014","unstructured":"Beaufort CM, Helmijr JC, Piskorz AM, Hoogstraat M, Ruigrok-Ritstier K, Besselink N, et al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One. 2014;9:e103988.","journal-title":"PLoS One"},{"key":"3466_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ebiom.2019.10.037","volume":"49","author":"Q Li","year":"2019","unstructured":"Li Q, Zhu CC, Ni B, Zhang ZZ, Jiang SH, Hu LP, et al. Lysyl oxidase promotes liver metastasis of gastric cancer via facilitating the reciprocal interactions between tumor cells and cancer associated fibroblasts. EBioMedicine. 2019;49:157\u201371.","journal-title":"EBioMedicine"},{"key":"3466_CR32","doi-asserted-by":"publisher","first-page":"6481","DOI":"10.7150\/jca.33223","volume":"10","author":"L Zhao","year":"2019","unstructured":"Zhao L, Niu H, Liu Y, Wang L, Zhang N, Zhang G, et al. LOX inhibition downregulates MMP-2 and MMP-9 in gastric cancer tissues and cells. J Cancer. 2019;10:6481\u201390.","journal-title":"J Cancer"},{"key":"3466_CR33","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1038\/bjc.2013.535","volume":"109","author":"T Osawa","year":"2013","unstructured":"Osawa T, Ohga N, Akiyama K, Hida Y, Kitayama K, Kawamoto T, et al. Lysyl oxidase secreted by tumour endothelial cells promotes angiogenesis and metastasis. Br J Cancer. 2013;109:2237\u201347.","journal-title":"Br J Cancer"},{"key":"3466_CR34","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1111\/jcmm.14074","volume":"23","author":"H Schilter","year":"2019","unstructured":"Schilter H, Findlay AD, Perryman L, Yow TT, Moses J, Zahoor A, et al. The lysyl oxidase like 2\/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis. J Cell Mol Med. 2019;23:1759\u201370.","journal-title":"J Cell Mol Med"},{"key":"3466_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/srep19608","volume":"6","author":"M Nilsson","year":"2016","unstructured":"Nilsson M, Adamo H, Bergh A, Halin Bergstrom S. Inhibition of Lysyl oxidase and Lysyl oxidase-like enzymes has tumour-promoting and tumour-suppressing roles in experimental prostate cancer. Sci Rep. 2016;6:19608.","journal-title":"Sci Rep"},{"key":"3466_CR36","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s10549-012-1986-8","volume":"134","author":"LC Chen","year":"2012","unstructured":"Chen LC, Tu SH, Huang CS, Chen CS, Ho CT, Lin HW, et al. Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway. Breast Cancer Res Treat. 2012;134:989\u20131004.","journal-title":"Breast Cancer Res Treat"},{"key":"3466_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01418-1","volume":"20","author":"A Le Naour","year":"2020","unstructured":"Le Naour A, Koffi Y, Diab M, Le Guennec D, Rouge S, Aldekwer S, et al. EO771, the first luminal B mammary cancer cell line from C57BL\/6 mice. Cancer Cell Int. 2020;20:328.","journal-title":"Cancer Cell Int"},{"key":"3466_CR38","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou C, Sonzogni O, De Oliveria Taveira M, Mehta AK, Kothari A, Wang D, et al. PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 2019;9:722\u201337.","journal-title":"Cancer Discov"},{"key":"3466_CR39","doi-asserted-by":"crossref","unstructured":"Luo Y, Xia Y, Liu D, Li X, Li H, Liu J et al. Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell. 2024;187:4905\u20134925.e24.","DOI":"10.1016\/j.cell.2024.06.013"},{"key":"3466_CR40","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/0014-4827(88)90265-0","volume":"175","author":"NP Singh","year":"1988","unstructured":"Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988;175:184\u201391.","journal-title":"Exp Cell Res"},{"key":"3466_CR41","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/0006-291X(84)90411-X","volume":"123","author":"O Ostling","year":"1984","unstructured":"Ostling O, Johanson KJ. Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells. Biochem Biophys Res Commun. 1984;123:291\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"3466_CR42","doi-asserted-by":"publisher","first-page":"166","DOI":"10.4161\/nucl.11176","volume":"1","author":"G Coster","year":"2010","unstructured":"Coster G, Goldberg M. The cellular response to DNA damage: a focus on MDC1 and its interacting proteins. Nucleus. 2010;1:166\u201378.","journal-title":"Nucleus"},{"key":"3466_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2020.102948","volume":"95","author":"SE Ruff","year":"2020","unstructured":"Ruff SE, Logan SK, Garabedian MJ, Huang TT. Roles for MDC1 in cancer development and treatment. DNA Repair. 2020;95:102948.","journal-title":"DNA Repair"},{"key":"3466_CR44","doi-asserted-by":"crossref","unstructured":"Sharif SB, Zamani N, Chadwick BP. BAZ1B the protean protein. Genes. 2021;12:1541.","DOI":"10.3390\/genes12101541"},{"key":"3466_CR45","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nature07849","volume":"458","author":"PJ Cook","year":"2009","unstructured":"Cook PJ, Ju BG, Telese F, Wang X, Glass CK, Rosenfeld MG. Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature. 2009;458:591\u20136.","journal-title":"Nature"},{"key":"3466_CR46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature07668","volume":"457","author":"A Xiao","year":"2009","unstructured":"Xiao A, Li H, Shechter D, Ahn SH, Fabrizio LA, Erdjument-Bromage H, et al. WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activity. Nature. 2009;457:57\u201362.","journal-title":"Nature"},{"key":"3466_CR47","doi-asserted-by":"publisher","first-page":"5395","DOI":"10.1038\/sj.onc.1210608","volume":"26","author":"N Avvakumov","year":"2007","unstructured":"Avvakumov N, Cote J. The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene. 2007;26:5395\u2013407.","journal-title":"Oncogene"},{"key":"3466_CR48","doi-asserted-by":"crossref","unstructured":"Li T, Petreaca RC, Forsburg SL Schizosaccharomyces pombe KAT5 contributes to resection and repair of a DNA double-strand break. Genetics 2021; 218.","DOI":"10.1093\/genetics\/iyab042"},{"key":"3466_CR49","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.dnarep.2019.02.005","volume":"76","author":"A Pozhidaeva","year":"2019","unstructured":"Pozhidaeva A, Bezsonova I. USP7: structure, substrate specificity, and inhibition. DNA Repair. 2019;76:30\u201339.","journal-title":"DNA Repair"},{"key":"3466_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.400","volume":"4","author":"YH Fan","year":"2013","unstructured":"Fan YH, Cheng J, Vasudevan SA, Dou J, Zhang H, Patel RH, et al. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis. 2013;4:e867.","journal-title":"Cell Death Dis"},{"key":"3466_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0611-1","volume":"16","author":"W Liu","year":"2017","unstructured":"Liu W, Li J, Song YS, Li Y, Jia YH, Zhao HD. Cdk5 links with DNA damage response and cancer. Mol Cancer. 2017;16:60.","journal-title":"Mol Cancer"},{"key":"3466_CR52","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/ncb2058","volume":"12","author":"E Huang","year":"2010","unstructured":"Huang E, Qu D, Zhang Y, Venderova K, Haque ME, Rousseaux MW, et al. The role of Cdk5-mediated apurinic\/apyrimidinic endonuclease 1 phosphorylation in neuronal death. Nat Cell Biol. 2010;12:563\u201371.","journal-title":"Nat Cell Biol"},{"key":"3466_CR53","doi-asserted-by":"publisher","first-page":"26765","DOI":"10.1074\/jbc.M109.092304","volume":"285","author":"S Courapied","year":"2010","unstructured":"Courapied S, Sellier H, de Carne Trecesson S, Vigneron A, Bernard AC, Gamelin E, et al. The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition. J Biol Chem. 2010;285:26765\u201378.","journal-title":"J Biol Chem"},{"key":"3466_CR54","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/ncb1829","volume":"11","author":"B Tian","year":"2009","unstructured":"Tian B, Yang Q, Mao Z. Phosphorylation of ATM by Cdk5 mediates DNA damage signalling and regulates neuronal death. Nat Cell Biol. 2009;11:211\u20138.","journal-title":"Nat Cell Biol"},{"key":"3466_CR55","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","volume":"153","author":"WA Whyte","year":"2013","unstructured":"Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153:307\u201319.","journal-title":"Cell"},{"key":"3466_CR56","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Loven","year":"2013","unstructured":"Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153:320\u201334.","journal-title":"Cell"},{"key":"3466_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0915-9","volume":"17","author":"B Donati","year":"2018","unstructured":"Donati B, Lorenzini E, Ciarrocchi A. BRD4 and Cancer: going beyond transcriptional regulation. Mol Cancer. 2018;17:164.","journal-title":"Mol Cancer"},{"key":"3466_CR58","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202318459","volume":"15","author":"L Pascual-Reguant","year":"2023","unstructured":"Pascual-Reguant L, Serra-Camprubi Q, Datta D, Cianferoni D, Kourtis S, Ganez-Zapater A, et al. Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer. EMBO Mol Med. 2023;15:e18459.","journal-title":"EMBO Mol Med"},{"key":"3466_CR59","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41418-018-0246-9","volume":"26","author":"F Mantovani","year":"2019","unstructured":"Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019;26:199\u2013212.","journal-title":"Cell Death Differ"},{"key":"3466_CR60","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1158\/2159-8290.CD-22-0787","volume":"13","author":"P Dharanipragada","year":"2023","unstructured":"Dharanipragada P, Zhang X, Liu S, Lomeli SH, Hong A, Wang Y, et al. Blocking genomic instability prevents acquired resistance to MAPK inhibitor therapy in melanoma. Cancer Discov. 2023;13:880\u2013909.","journal-title":"Cancer Discov"},{"key":"3466_CR61","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"3466_CR62","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1158\/1535-7163.MCT-20-0992","volume":"20","author":"N Goel","year":"2021","unstructured":"Goel N, Foxall ME, Scalise CB, Wall JA, Arend RC. Strategies in overcoming homologous recombination proficiency and PARP inhibitor resistance. Mol Cancer Ther. 2021;20:1542\u20139.","journal-title":"Mol Cancer Ther"},{"key":"3466_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188435","volume":"1874","author":"B Wen","year":"2020","unstructured":"Wen B, Xu LY, Li EM. LOXL2 in cancer: regulation, downstream effectors and novel roles. Biochim Biophys Acta Rev Cancer. 2020;1874:188435.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3466_CR64","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1634\/theoncologist.2017-0024","volume":"22","author":"AB Benson 3rd","year":"2017","unstructured":"Benson AB 3rd, Wainberg ZA, Hecht JR, Vyushkov D, Dong H, Bendell J, et al. A phase II randomized, double-blind, placebo-controlled study of simtuzumab or placebo in combination with gemcitabine for the first-line treatment of pancreatic adenocarcinoma. Oncologist. 2017;22:241\u2013e215.","journal-title":"Oncologist"},{"key":"3466_CR65","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1634\/theoncologist.2016-0479","volume":"22","author":"JR Hecht","year":"2017","unstructured":"Hecht JR, Benson AB 3rd, Vyushkov D, Yang Y, Bendell J, Verma U, et al. A phase II, randomized, double-blind, placebo-controlled study of simtuzumab in combination with FOLFIRI for the second-line treatment of metastatic KRAS mutant colorectal adenocarcinoma. Oncologist. 2017;22:243\u2013e223.","journal-title":"Oncologist"},{"key":"3466_CR66","doi-asserted-by":"crossref","unstructured":"Ferreira S, Saraiva N, Rijo P, Fernandes AS. LOXL2 inhibitors and breast cancer progression. Antioxidants. 2021;10:312.","DOI":"10.3390\/antiox10020312"},{"key":"3466_CR67","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1111\/febs.13922","volume":"283","author":"N Herranz","year":"2016","unstructured":"Herranz N, Dave N, Millanes-Romero A, Pascual-Reguant L, Morey L, Diaz VM, et al. Lysyl oxidase-like 2 (LOXL2) oxidizes trimethylated lysine 4 in histone H3. FEBS J. 2016;283:4263\u201373.","journal-title":"FEBS J"},{"key":"3466_CR68","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41388-019-0969-1","volume":"39","author":"JP Cebria-Costa","year":"2020","unstructured":"Cebria-Costa JP, Pascual-Reguant L, Gonzalez-Perez A, Serra-Bardenys G, Querol J, Cosin M, et al. LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells. Oncogene. 2020;39:79\u2013121.","journal-title":"Oncogene"},{"key":"3466_CR69","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.1158\/0008-5472.CAN-22-0848","volume":"82","author":"X Lu","year":"2022","unstructured":"Lu X, Xin DE, Du JK, Zou QC, Wu Q, Zhang YS, et al. Loss of LOXL2 promotes uterine hypertrophy and tumor progression by enhancing H3K36ac-dependent gene expression. Cancer Res. 2022;82:4400\u201313.","journal-title":"Cancer Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03466-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03466-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03466-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:17:21Z","timestamp":1757179041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03466-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":69,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2025,8,25]]}},"alternative-id":["3466"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03466-1","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}